For patients with metastatic prostate cancer who have exhausted initial or first-line treatments like hormone therapy (also called androgen deprivation therapy or ADT) and chemotherapy, a promising ...

The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial ...

Applications are now open for the 2026 EANM Young Scientist Network Award. This new research award, supported by Advanced Accelerator Applications (a Novartis company), aims to accelerate innovative ...

LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new Companies to Watch report, Radioligand ...

In 2010, a volcano erupted in Iceland. For Dr. Oliver Sartor, a cancer research professor at the Tulane University School of Medicine, it was a problem. Stream Connecticut News for free, 24/7, ...

A recent study published in The Lancet Regional Health—Europe estimates that the number of patients eligible for radioligand therapies (RLTs) in the EU-27 could increase from 10,700–13,200 in 2025 to ...

Novartis is sitting at the center of a fast-growing oncology market as radioligand therapy gains momentum in cancer treatment. The therap ...

Interim results from a phase 3 trial supported the use of the radioligand therapy 177 Lu-DOTATATE (Lutathera) as first-line therapy to treat high-grade gastroenteropancreatic neuroendocrine tumors.

Radioligand therapies, which combine a therapeutic radionuclide with a cancer-targeting small molecule, aim to treat cancers while minimizing damage to healthy tissues. Until now, these had not been ...

Novartis launches Pluvicto, introducing a precision oncology treatment that delivers targeted radiation directly to cancer cells while limiting exposure to healthy tissue ...